Latest News & Features
Americas
Unlike in the EU, Canada does not have additional pharma patent protection to compensate for regulatory delays, but that looks set to change, as Shirley Liang, an IP lawyer in Canada, explains. 21 April 2016
Asia
The Indian government has invited public comments on draft regulatory guidelines for biosimilars, while patent law in this area has still to take shape. Sameer Sah, Nisha Austine and Jahnvi Shah of Khaitan & Co report. 14 April 2016
Americas
The BPCIA requires a biosimilar applicant to notify the reference product sponsor of its drug no later than 180 days before the first commercial marketing date. Darryl Woo, Erin Ator Thomson, Janice Ta and Wendy Wang of Vinson & Elkins report on some of the pressing issues in this area. 7 April 2016
Americas
In March, Merck unsuccessfully tried to invalidate a patent owned by Bristol-Myers Squibb covering metastatic skin cancer treatment. Ernest Linek of Banner & Witcoff reviews the arguments and the court’s ruling. 7 April 2016
Big Pharma
Owners of second medical use patents may need to think outside the box in terms of the relief they seek for infringement, says Katie Hutchinson of Bristows. 31 March 2016
Americas
No patent application directed to CRISPR has yet fallen foul of the EU’s Biotech Directive on the basis of the human embryo use exception, but the technology is still in its nascent stage. Ashley Roughton of Nabarro reports. 31 March 2016
Big Pharma
Despite a large body of EPO case law accepting second medical use claims that recite a novel technical effect, all eyes are on how courts in EPC member states will deal with infringement cases arising from such patents. Joachim Wachenfeld and Oswin Ridderbusch of Vossius & Partner report. 24 March 2016
Americas
Patent owners and petitioners in the life sciences industry who raise arguments surrounding commercial success during PTAB trials face substantive and procedural roadblocks, argue Christopher Jagoe and James McConnell of Kirkland & Ellis. 17 March 2016
Africa
The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications. 9 March 2016
Big Pharma
In February the English High Court ruled that Actavis had not indirectly infringed a patent owned by Eli Lilly directed to cancer drug Alimta. David Read of Bartle Read reports. 8 March 2016